Immune




Vanicef

Composition: Cefpodoxime Proxetil

Indication:

Labeled Indications

  • Chronic obstructive pulmonary disease, acute exacerbation: Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease caused by Streptococcus pneumoniaeHaemophilus influenzae, or Moraxella catarrhalis.
  • Cystitis, acute uncomplicated: Treatment of acute uncomplicated cystitis caused by Escherichia coliKlebsiella pneumoniaeProteus mirabilis, or Staphylococcus saprophyticus.
  • Otitis media, acute: Treatment of acute otitis media caused by S.pneumoniae, Streptococcus pyogenesH.influenzae (including beta-lactamase-producing strains), or M. catarrhalis (including beta-lactamase-producing strains).
  • Pneumonia, community-acquired: Treatment of community-acquired pneumonia caused by S. pneumoniae or H. influenzae (including beta-lactamase-producing strains).
  • Rhinosinusitis, acute bacterial: Treatment of acute bacterial rhinosinusitis caused by H. influenzae (including beta-lactamase-producing strains), S. pneumoniae, and M. catarrhalisNote: According to the Infectious Diseases Society of America guidelines for acute bacterial rhinosinusitis, cefpodoxime is recommended in combination with clindamycin due to concern for pneumococcal resistance.
  • Skin and soft tissue infection: Treatment of uncomplicated skin and soft tissue infection caused by Staphylococcus aureus (including penicillinase-producing strains) or S. pyogenes.
  • Streptococcal pharyngitis (group A): Treatment of pharyngitis or tonsillitis caused by S. pyogenes.

Off Label Uses

Urinary tract infection, complicated (including pyelonephritis) Clinical experience suggests the utility of cefpodoxime as an alternative agent in the treatment of acute complicated urinary tract infection (including pyelonephritis) after administration of an appropriate parenteral agent

Package: Oral suspension; 50mg/5ml-60mL, 100mg/5mL-60mL. F.C.Tablets; 10 cap.

For more details: